WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H524735
CAS#: 149394-66-1 (hydrate)
Description: Cidofovir, also known as Vistide, is an injectable antiviral medication primarily used as a treatment for cytomegalovirus (CMV) retinitis- an infection of the retina of the eye in people with AIDS.Cidofovir is an acyclic nucleoside phosphonate. In vitro, cidofovir is converted to cidofovir diphosphate which incorporates into viral DNA, selectively inhibiting CMV replication and CMV DNA synthesis with IC50 values of 0.1 μM. Cidofovir has significantly long-lasting antiviral action because of the long half-life of its metabolites whose cellular uptake is slow due to the presence of the negatively charged phosphonate group. It has also demonstrated remarkable activity as an antitumor agent in a variety of animal models of tumor growth.
Hodoodo Cat#: H524735
Name: Cidofovir hydrate
CAS#: 149394-66-1 (hydrate)
Chemical Formula: C8H18N3O8P
Exact Mass: 0.00
Molecular Weight: 315.220
Elemental Analysis: C, 30.48; H, 5.76; N, 13.33; O, 40.61; P, 9.83
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 149394-66-1 (hydrate) 127749-27-3 (sodium) 113852-37-2 (free base),
Synonym: Cidofovir; Vistide; HPMPC; Cidofovir anhydrous; Cidofovirum; GS-504;HPMPC; Pfizer brand of cidofovir;Vistide.
IUPAC/Chemical Name: (((S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)phosphonic acid, dihydrate
InChi Key: FPKARFMSZDBYQF-ILKKLZGPSA-N
InChi Code: InChI=1S/C8H14N3O6P.2H2O/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16;;/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16);2*1H2/t6-;;/m0../s1
SMILES Code: OC[C@@H](OCP(O)(O)=O)CN1C=CC(N)=NC1=O.[H]O[H].[H]O[H]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 315.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Ganapathi L, Arnold A, Jones S, Patterson A, Graham D, Harper M, Levy O. Use of cidofovir in pediatric patients with adenovirus infection. F1000Res. 2016 Apr 26;5:758. doi: 10.12688/f1000research.8374.1. eCollection 2016. PubMed PMID: 27239277; PubMed Central PMCID: PMC4863673.
2: Epstein JB, Gharapetian S, Rejali AR, Zabner R, Lill M, Tzachanis D. Complex management of resistant oral herpes simplex virus infection following hematopoietic stem cell transplantation: potential role of topical cidofovir. Support Care Cancer. 2016 May 10. [Epub ahead of print] PubMed PMID: 27165053.
3: Bonvicini F, Bua G, Manaresi E, Gallinella G. Enhanced inhibition of parvovirus B19 replication by cidofovir in extendedly exposed erythroid progenitor cells. Virus Res. 2016 Apr 9;220:47-51. doi: 10.1016/j.virusres.2016.04.002. [Epub ahead of print] PubMed PMID: 27071853.
4: Leitenberger JJ, Abdelmalek M, Wang RC, Strasfeld L, Hopkins RS. Two cases of trichodysplasia spinulosa responsive to compounded topical cidofovir 3% cream. JAAD Case Rep. 2015 Nov 24;1(6):S33-5. doi: 10.1016/j.jdcr.2015.09.019. eCollection 2015 Nov. PubMed PMID: 27051806; PubMed Central PMCID: PMC4809585.
5: Deutsch E, Haie-Meder C, Bayar MA, Mondini M, Laporte M, Mazeron R, Adam J, Varga A, Vassal G, Magné N, Chargari C, Lanoy E, Pautier P, Levy A, Soria JC. Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients. Oncotarget. 2016 Mar 21. doi: 10.18632/oncotarget.8224. [Epub ahead of print] PubMed PMID: 27016411.
6: Ellrichmann G, Behrendt V, Grunwald C, Schlottmann R, Lukas C, Gold R. Cidofovir for treatment of progressive multifocal leukoencephalopathy in a newly diagnosed sarcoidosis patient - a valid therapeutic option? J Neurol Sci. 2016 Mar 15;362:341-3. doi: 10.1016/j.jns.2016.02.011. Epub 2016 Feb 6. PubMed PMID: 26944175.
7: Sakurada M, Kondo T, Umeda M, Kawabata H, Yamashita K, Takaori-Kondo A. Successful treatment with intravesical cidofovir for virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: A case report and a review of the literature. J Infect Chemother. 2016 Feb 15. pii: S1341-321X(16)00034-9. doi: 10.1016/j.jiac.2016.01.013. [Epub ahead of print] PubMed PMID: 26898668.
8: Wilkens H, Sester M. Treatment of Cytomegalovirus Infection with Cidofovir and CMV Immune Globulin in a Lung Transplant Recipient. Case Rep Transplant. 2016;2016:4560745. doi: 10.1155/2016/4560745. Epub 2016 Jan 13. PubMed PMID: 26885432; PubMed Central PMCID: PMC4738720.
9: Murono S, Nakanishi Y, Tsuji A, Endo K, Kondo S, Wakisaka N, Yoshizaki T. Intralesional cidofovir injection for recurrent respiratory papillomatosis in Japan. Auris Nasus Larynx. 2016 Feb 6. pii: S0385-8146(16)30028-1. doi: 10.1016/j.anl.2016.01.005. [Epub ahead of print] PubMed PMID: 26860235.
10: Topalis D, Nogueira TC, De Schutter T, El Amri C, Krečmerová M, Naesens L, Balzarini J, Andrei G, Snoeck R. Resistance to the nucleotide analogue cidofovir in HPV(+) cells: a multifactorial process involving UMP/CMP kinase 1. Oncotarget. 2016 Mar 1;7(9):10386-401. doi: 10.18632/oncotarget.7006. PubMed PMID: 26824416.
11: Usoro A, Batts A, Sarria JC. Intravenous Foscarnet With Topical Cidofovir for Chronic Refractory Genital Herpes in a Patient With AIDS. J Investig Med High Impact Case Rep. 2015 Dec 11;3(4):2324709615621095. doi: 10.1177/2324709615621095. eCollection 2015 Oct-Dec. PubMed PMID: 26788527; PubMed Central PMCID: PMC4710108.
12: Sendagorta E, Bernardino JI, Álvarez-Gallego M, Feíto M, Feltes R, Beato MJ, Pérez-Molina JA, Yllescas M, Díaz-Almirón M, Arribas JR, González-García J, Herranz P; CIDAN127412 GESIDA Study Group. Topical cidofovir to treat high-grade anal intraepithelial neoplasia in HIV-infected patients: a pilot clinical trial. AIDS. 2016 Jan 2;30(1):75-82. doi: 10.1097/QAD.0000000000000886. PubMed PMID: 26731755.
13: Philippe M, Ranchon F, Gilis L, Schwiertz V, Vantard N, Ader F, Labussiere-Wallet H, Thomas X, Nicolini FE, Wattel E, Ducastelle-Leprêtre S, Barraco F, Lebras L, Salles G, Michallet M, Rioufol C. Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Apr;22(4):723-30. doi: 10.1016/j.bbmt.2015.12.009. Epub 2015 Dec 21. PubMed PMID: 26718666.
14: Santesteban R, Feito M, Mayor A, Beato M, Ramos E, de Lucas R. Trichodysplasia Spinulosa in a 20-Month-Old Girl With a Good Response to Topical Cidofovir 1%. Pediatrics. 2015 Dec;136(6):e1646-9. doi: 10.1542/peds.2015-0953. PubMed PMID: 26620059.
15: Aitken SL, Zhou J, Ghantoji SS, Kontoyiannis DP, Jones RB, Tam VH, Chemaly RF. Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. J Antimicrob Chemother. 2016 Mar;71(3):727-30. doi: 10.1093/jac/dkv393. Epub 2015 Nov 26. PubMed PMID: 26612873.
16: Ledbetter EC, Spertus CB, Pennington MR, Van de Walle GR, Judd BE, Mohammed HO. In Vitro and In Vivo Evaluation of Cidofovir as a Topical Ophthalmic Antiviral for Ocular Canine Herpesvirus-1 Infections in Dogs. J Ocul Pharmacol Ther. 2015 Dec;31(10):642-9. doi: 10.1089/jop.2015.0024. Epub 2015 Sep 29. PubMed PMID: 26418618.
17: Tuğcu-Demiröz F, Acartürk F, Özkul A. Preparation and characterization of bioadhesive controlled-release gels of cidofovir for vaginal delivery. J Biomater Sci Polym Ed. 2015;26(17):1237-55. doi: 10.1080/09205063.2015.1082808. Epub 2015 Sep 24. PubMed PMID: 26300445.
18: Moore E, Kovarik C. Intralesional cidofovir for the treatment of a plantar wart. J Am Acad Dermatol. 2015 Jul;73(1):e23-4. doi: 10.1016/j.jaad.2015.02.1143. PubMed PMID: 26089066.
19: Pozzuto T, Röger C, Kurreck J, Fechner H. Enhanced suppression of adenovirus replication by triple combination of anti-adenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir. Antiviral Res. 2015 Aug;120:72-8. doi: 10.1016/j.antiviral.2015.05.010. Epub 2015 May 27. PubMed PMID: 26026665.
20: Rascon J, Verkauskas G, Pasauliene R, Zubka V, Bilius V, Rageliene L. Intravesical cidofovir to treat BK virus-associated hemorrhagic cystitis in children after hematopoietic stem cell transplantation. Pediatr Transplant. 2015 Jun;19(4):E111-4. doi: 10.1111/petr.12477. Epub 2015 Apr 16. PubMed PMID: 25882393.
